GleamWall
中文EN

BNTC Benitec Biopharma Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1808898 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-18.4%
TTM EPS YoY4.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-37.6%
ROA-36.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets5.3%
Debt / equity0.00x
Current ratio19.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.34x
Accruals ratio-23.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q42025-06-302025Q32025-03-312024Q22024-12-31
Income statement
Revenue——$0$0$0—$0$0
R&D expense$8.62M$7.89M$6.30M$5.83M$3.37M$2.87M$6.50M$5.38M
SG&A expense$5.86M$6.54M$7.28M$7.54M$6.43M$6.97M$8.84M$5.42M
Operating income-$14.48M-$14.43M-$13.58M-$13.38M-$9.80M-$9.83M-$15.34M-$10.80M
Net income-$12.93M-$12.81M-$11.94M-$11.84M-$8.96M-$8.80M-$14.50M-$9.55M
EBITDA-$14.46M-$14.41M-$13.57M-$13.36M-$9.79M-$9.82M-$15.32M-$10.79M
EPS (basic)-0.26—-0.24-0.26-0.22-0.21-0.38-0.26
EPS (diluted)-0.26—-0.24-0.26-0.22-0.21-0.38-0.26
Weighted avg. shares (diluted)49.49M—49.39M45.97M41.52M41.16M38.60M37.25M
Balance sheet
Cash & equivalents$176.37M$179.97M$184.76M$188.79M$94.59M$97.86M$103.45M$78.34M
Current assets$178.10M$181.69M$186.02M$189.59M$95.08M$98.52M$104.01M$78.71M
PP&E, net$110,000$178,000$116,000$115,000$118,000$131,000$145,000$151,000
Total assets$179.10M$182.62M$187.00M$190.68M$96.03M$99.59M$105.21M$79.07M
Current liabilities$9.08M$5.34M$3.27M$2.80M$2.02M$1.80M$7.03M$3.09M
Total liabilities$9.45M$5.61M$3.67M$3.32M$2.43M$2.30M$7.64M$3.13M
Shareholders' equity$169.65M$177.01M$183.33M$187.36M$93.60M$97.30M$97.57M$75.94M
Shares outstanding34.89M34.42M34.35M34.25M26.25M26.25M25.55M23.45M
Cash flow statement
Operating cash flow-$3.62M-$4.94M-$4.45M-$3.78M-$3.35M-$8.21M-$3.09M-$7.70M
Capital expenditure—$79,000$15,000——$0$6,000—
Free cash flow—-$5.02M-$4.47M——-$8.21M-$3.09M—
Investing cash flow$0-$79,000-$15,000-$11,000$0$0-$6,000-$12,000
Financing cash flow$0$241,000$506,000$98.23M$0$2.54M$28.41M$17.87M
Depreciation & amortization$17,000$17,000$14,000$14,000$13,000$14,000$13,000$14,000
Stock-based compensation$5.51M$6.26M$7.59M$7.38M$5.18M$13.45M$7.74M$3.14M

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.